Home > Insider Trading > Filing (0001209191-14-004055)

Filing Details

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
914475	Neurocrine Biosciences Inc	NBIX	Biological Products, (No Disgnostic Substances) (2836)	330525145

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1423837	P. Haig Bozigian	12780 El Camino Real San Diego CA 92130	Chief Development Officer	No	Yes	No	No

Reported Non-Derivative Transactions

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership
Common Stock	Acquisiton	2014-01-17	20,000	$2.59	98,579	No	4	M	Direct
Common Stock	Acquisiton	2014-01-17	5,000	$5.12	103,579	No	4	M	Direct
Common Stock	Disposition	2014-01-17	25,000	$20.00	78,579	No	4	S	Direct

Equity Swap Involved	Form Type	Code	Nature of Ownership
No	4	M	Direct
No	4	M	Direct
No	4	S	Direct

Reported Derivative Transactions

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Common Stock	STOCK OPTION	Acquisiton	2014-01-16	75,000	$19.59	75,000	$19.59
Common Stock	RESTRICTED STOCK UNIT	Acquisiton	2014-01-16	13,000	$0.00	13,000	$0.00
Common Stock	RESTRICTED STOCK UNIT	Acquisiton	2014-01-16	75,000	$0.00	75,000	$0.00
Common Stock	INCENTIVE STOCK OPTION	Disposition	2014-01-17	5,000	$5.12	5,000	$5.12
Common Stock	INCENTIVE STOCK OPTION	Disposition	2014-01-17	20,000	$2.59	20,000	$2.59

Remaning Holdings	Exercise Date	Expiration Date	Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
75,000	2014-02-16	2024-01-16	No	4	A	Direct
13,000			No	4	A	Direct
75,000		2019-01-16	No	4	A	Direct
10,000	2009-02-27	2015-02-27	No	4	M	Direct
50,000	2010-06-11	2017-05-11	No	4	M	Direct

Footnotes

Exercise of in-the-money derivative security
The disposition reported in this Form 4 was effected by a broker pursuant to instruction set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person at least 90 days prior to the transaction date in Box 3 above. Additionally, Issuer policy restricts the reporting person from amending, canceling, suspending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of such plan.
Represents option of which 1/48th of the shares underlying the option becomes vested and exercisable on February 16, 2014, an additional 1/48th of the shares underlying the option becomes vested and exercisable each month thereafter.
Each restricted stock unit represents a contingent right to receive one share of Neurocrine Common Stock.
The restricted stock units will vest annually at 1/4 of the units vesting on January 16, 2015, January 16, 2016, January 16, 2017, and January 16, 2018
50,000 of these restricted stock units will vest upon the Company achieving the primary endpoint in a U.S. Food and Drug Administration ("FDA") approved Phase 3 study, while the remaining 25,000 restricted stock units will vest upon the Company obtaining FDA approval of a New Drug Application. The vesting provisions of these RSU are exclusive of the elagolix program.